Status:
UNKNOWN
Measuring and Monitoring Blood Glucose Levels Utilizing Non-invasive Blood Glucose Monitoring Device
Lead Sponsor:
GlucoVista
Conditions:
Diabetes Mellitus Type 1
Eligibility:
All Genders
18-65 years
Brief Summary
Adequate glycemic control in patients with Diabetes Mellitus (DM) is a desired therapeutic goal that can be achieved with a true non-invasive device offering the likelihood of continuous glucose monit...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Type 1 Diabetic patient.
- Ages: 18 to 65.
- Signed informed consent.
- HbA1c of 6%-9% at screening.
- Males- not involved in active military duty.
- Females-non-child bearing potential or females of child-bearing potential who have a negative pregnancy test (HCG in blood or urine) within 72 hours of informed consent.
- Exclusion criteria:
- Active systemic or local infection.
- Any medical condition that, by the investigator judgment, will increase the risk from Hyper and Hypo-Glycemic experiment: seizures, heart disease, hypoglycemia unawareness etc.
- History of malignancy, radiotherapy, or chemotherapy for malignancy (except BCC of the skin)
Exclusion
Key Trial Info
Start Date :
September 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01508065
Start Date
September 1 2012
Last Update
February 20 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel, 91120
2
Hadassah Medical Organization
Jerusalem, Israel